Serum methionine metabolites are risk factors for metastatic prostate cancer progression

PLoS ONE

Volumn 6, Issue 8, 2011, Pages

  Stabler, Sally ^a   Koyama, Tatsuki ^b   Zhao, Zhiguo ^b   Martinez Ferrer, Magaly ^c   Allen, Robert H ^a   Luka, Zigmund ^b   Loukachevitch, Lioudmila V ^b   Clark, Peter E ^b   Wagner, Conrad ^b   Bhowmick, Neil A ^b,d  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^d CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYSTATHIONINE; CYSTEINE; HOMOCYSTEINE; METHIONINE; PROSTATE SPECIFIC ANTIGEN; SARCOSINE; TUMOR MARKER;

ADULT; AMINO ACID BLOOD LEVEL; AMINO ACID METABOLISM; AMINO ACID URINE LEVEL; ARTICLE; BLOOD SAMPLING; CANCER GROWTH; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASS FRAGMENTOGRAPHY; METASTASIS; PROSTATE CANCER; RISK ASSESSMENT; URINALYSIS; BLOOD; DISEASE COURSE; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; PROSTATE TUMOR; RECEIVER OPERATING CHARACTERISTIC; RECURRENT DISEASE; RISK FACTOR; STATISTICAL MODEL; URINE;

DISEASE PROGRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; METHIONINE; MIDDLE AGED; NEOPLASM METASTASIS; PROPORTIONAL HAZARDS MODELS; PROSTATIC NEOPLASMS; RECURRENCE; RISK FACTORS; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 80051518635     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0022486     Document Type: Article

References (34)

1. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, et al. (2002) Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst 94: 981-990.
2. Andriole GL, Crawford ED, Grubb RL 3rd, Buys SS, Chia D, et al. (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360: 1310-1319.
3. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, et al. (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360: 1320-1328.
4. Thompson IM, Pauler DK, Goodman PJ, Tangen CM, Lucia MS, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 350: 2239-2246.
5. Thompson IM, Ankerst DP, Chi C, Lucia MS, Goodman PJ, et al. (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. Jama 294: 66-70.
6. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, et al. (2008) Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 14: 7790-7797.
7. Thompson KE, Hernandez J, Canby-Hagino ED, Troyer D, Thompson IM, (2005) Prognostic features in men who died of prostate cancer. J Urol 174: 553-556; discussion 556.
8. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, et al. (2009) Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 457: 910-914.
9. Luka Z, Mudd SH, Wagner C, (2009) Glycine N-methyltransferase and regulation of S-adenosylmethionine levels. J Biol Chem 284: 22507-22511.
10. Levy HL, Coulombe JT, Benjamin R, (1984) Massachusetts Metabolic Disorders Screening Program: III. Sarcosinemia. Pediatrics 74: 509-513.
11. Allen RH, Stabler SP, Lindenbaum J, (1993) Serum betaine, N,N-dimethylglycine and N-methylglycine levels in patients with cobalamin and folate deficiency and related inborn errors of metabolism. Metabolism 42: 1448-1460.
12. Allen RH, Stabler SP, Savage DG, Lindenbaum J, (1993) Elevation of 2-methylcitric acid I and II levels in serum, urine, and cerebrospinal fluid of patients with cobalamin deficiency. Metabolism 42: 978-988.
13. Stabler SP, Marcell PD, Podell ER, Allen RH, Savage DG, et al. (1988) Elevation of total homocysteine in the serum of patients with cobalamin or folate deficiency detected by capillary gas chromatography-mass spectrometry. J Clin Invest 81: 466-474.
14. Horne DW, Patterson D, (1988) Lactobacillus casei microbiological assay of folic acid derivatives in 96-well microtiter plates. Clinical Chemistry 34: 2357-2359.
15. Barr DB, Wilder LC, Caudill SP, Gonzalez AJ, Needham LL, et al. (2005) Urinary creatinine concentrations in the U.S. population: implications for urinary biologic monitoring measurements. Environ Health Perspect 113: 192-200.
16. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172.
17. Grambsch P, Therneau T, (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrica 81: 515-526.
18. Baik HW, Russell RM, (1999) Vitamin B12 deficiency in the elderly. Annu Rev Nutr 19: 357-377.
19. Roehl KA, Antenor JA, Catalona WJ, (2002) Serial biopsy results in prostate cancer screening study. J Urol 167: 2435-2439.
20. Capitanio U, Karakiewicz PI, Jeldres C, Briganti A, Gallina A, et al. (2009) The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. Int J Urol 16: 526-529.
21. Beam CA, Gao W, Macias V, Liang W, Balla AK, (2009) Sequential testing approach as an efficient and easier alternative for the validation of new predictive technologies in the clinic. J Clin Oncol 27: 1087-1090.
22. Finkelstein JD, Kyle WE, Martin JL, Pick AM, (1975) Activation of cystathionine synthase by adenosylmethionine and adenosylethionine. Biochem Biophys Res Commun 66: 81-87.
23. Jentzmik F, Stephan C, Miller K, Schrader M, Erbersdobler A, et al. (2010) Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. Eur Urol 58: 12-18; discussion 20-11.
24. Hewavitharana AK, (2010) Letter to the editor. Eur Urol 58: e39-e40.
25. Jentzmik F, Stephan C, Lein M, Miller K, Kamlage B, et al. (2011) Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. J Urol 185: 706-11.
26. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA, (2010) Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 47: 282.
27. Cao DL, Ye DW, Zhu Y, Zhang HL, Wang YX, et al. (2011) Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of differentalgorithms of sarcosine in urine. Prostate Cancer Prostatic Dis 14: 166-72.
28. Martinez-Chantar ML, Vazquez-Chantada M, Ariz U, Martinez N, Varela M, et al. (2008) Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice. Hepatology 47: 1191-1199.
29. Lin J, Lee IM, Song Y, Cook NR, Selhub J, et al. (2010) Plasma homocysteine and cysteine and risk of breast cancer in women. Cancer Res 70: 2397-2405.
30. Khan N, Afaq F, Mukhtar H, (2010) Lifestyle as risk factor for cancer: Evidence from human studies. Cancer Lett 293: 133-143.
31. Elshorbagy AK, Nurk E, Gjesdal CG, Tell GS, Ueland PM, et al. (2008) Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism? Am J Clin Nutr 88: 738-746.
32. Kane CJ, Im R, Amling CL, Presti JC Jr, Aronson WJ, et al. (2010) Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 76: 695-700.
33. Heady JE, Kerr SJ, (1975) Alteration of glycine N-methyltransferase activity in fetal, adult, and tumor tissues. Cancer Research 35: 640-643.
34. Huang YC, Lee CM, Chen M, Chung MY, Chang YH, et al. (2007) Haplotypes, loss of heterozygosity, and expression levels of glycine N-methyltransferase in prostate cancer. Clin Cancer Res 13: 1412-1420.